The ongoing efforts to identify better, highly potent and selective compounds that selectively inhibit individual HDMs will be of great help to further delineate the individual roles of members of this enzyme family in AR signaling and prostate cancer [132]. The gene discussed is AR; the disease is prostate carcinoma.